224 related articles for article (PubMed ID: 9469448)
1. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor.
Mokyr MB; Kalinichenko TV; Gorelik L; Bluestone JA
J Immunol; 1998 Feb; 160(4):1866-74. PubMed ID: 9469448
[TBL] [Abstract][Full Text] [Related]
2. Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.
Mokyr MB; Barker E; Weiskirch LM; Takesue BY; Pyle JM
Cancer Res; 1989 Aug; 49(16):4597-606. PubMed ID: 2568174
[TBL] [Abstract][Full Text] [Related]
3. Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.
Mokyr MB; Rubin M; Newell KA; Prokhorova A; Bluestone JA
J Immunol; 1993 Nov; 151(9):4838-46. PubMed ID: 8409442
[TBL] [Abstract][Full Text] [Related]
4. Importance of TNF production for the curative effectiveness of low dose melphalan therapy for mice bearing a large MOPC-315 tumor.
Gorelik L; Rubin M; Prokhorova A; Mokyr MB
J Immunol; 1995 Apr; 154(8):3941-51. PubMed ID: 7706732
[TBL] [Abstract][Full Text] [Related]
5. Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy.
Takesue BY; Pyle JM; Mokyr MB
Cancer Res; 1990 Dec; 50(23):7641-9. PubMed ID: 2123740
[TBL] [Abstract][Full Text] [Related]
6. Cooperation between staphylococcal enterotoxin B and low dose melphalan in the cure of mice bearing a large MOPC-315 tumor and extensive metastases.
Rubin M; Bluestone JA; Newell KA; Prokhorova A; Mokyr MB
J Immunol; 1994 Apr; 152(7):3522-9. PubMed ID: 8144932
[TBL] [Abstract][Full Text] [Related]
7. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
Barker E; Wise JA; Dray S; Mokyr MB
Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
[TBL] [Abstract][Full Text] [Related]
8. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
Barker E; Mokyr MB
Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 2 requirement for the in vitro generation of antitumor cytotoxicity by thymocytes from melphalan-cured MOPC-315 tumor bearers.
Mokyr MB; Bartik MM; Ahn MC
Cancer Res; 1989 Feb; 49(4):870-6. PubMed ID: 2783557
[TBL] [Abstract][Full Text] [Related]
10. Melphalan-induced enhancement of antitumor immune reactivity in thymocytes of adult BALB/c mice bearing a large MOPC-315 tumor.
Bartik MM; Takesue BY; Mokyr MB
Cancer Res; 1987 Sep; 47(18):4848-55. PubMed ID: 3497711
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of antitumor CTL response by GM-CSF involves a B7-dependent mechanism.
Mokyr MB; Kalinichenko TV; Gorelik L
Cell Immunol; 1997 Jun; 178(2):152-61. PubMed ID: 9225006
[TBL] [Abstract][Full Text] [Related]
12. Insight into the mechanism of TCR-V beta 8+/CD8+ T cell-mediated MOPC-315 tumor eradication.
Mokyr MB; Prokhorova A; Rubin M; Bluestone JA
J Immunol; 1994 Oct; 153(7):3123-34. PubMed ID: 8089490
[TBL] [Abstract][Full Text] [Related]
13. B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells.
Sojka DK; La Motte RN; Mokyr MB
Cancer Immunol Immunother; 2000 Apr; 49(1):10-22. PubMed ID: 10782862
[TBL] [Abstract][Full Text] [Related]
14. Importance of IL-10 for CTLA-4-mediated inhibition of tumor-eradicating immunity.
Jovasevic VM; Gorelik L; Bluestone JA; Mokyr MB
J Immunol; 2004 Feb; 172(3):1449-54. PubMed ID: 14734721
[TBL] [Abstract][Full Text] [Related]
15. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.
Gorelik L; Prokhorova A; Mokyr MB
Cancer Immunol Immunother; 1994 Aug; 39(2):117-26. PubMed ID: 8044831
[TBL] [Abstract][Full Text] [Related]
16. Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells.
Gorelik L; Bar-Dagan Y; Mokyr MB
J Immunol; 1996 Jun; 156(11):4298-308. PubMed ID: 8666801
[TBL] [Abstract][Full Text] [Related]
17. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
Adler A; Altbaum I
J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
[TBL] [Abstract][Full Text] [Related]
18. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
J Immunol; 1999 Apr; 162(8):4817-23. PubMed ID: 10202025
[TBL] [Abstract][Full Text] [Related]
19. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
Weiskirch LM; Mokyr MB
Int J Cancer; 1992 Apr; 51(1):84-92. PubMed ID: 1563847
[TBL] [Abstract][Full Text] [Related]
20. Low-dose-melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC-315 tumor bearers and the role of interferon gamma in the therapeutic outcome.
Gorelik L; Mokyr MB
Cancer Immunol Immunother; 1995 Dec; 41(6):363-74. PubMed ID: 8635194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
